A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs CV 9202 (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 05 Jun 2018 Trial design was presented at 54th Annual Meeting of the American Society of Clinical Oncology.
- 19 Jan 2018 Planned End Date changed from 1 Jul 2024 to 1 Dec 2024.
- 19 Jan 2018 Planned primary completion date changed from 1 Oct 2020 to 1 Mar 2021.